RightFit
RecruitingPhase 1

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests BMS-986460 in men with prostate cancer that has spread and keeps growing despite treatment to lower male hormones. It looks at how safe the drug is, how well men tolerate it, and early signs of whether it works.

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have prostate adenocarcinoma, a type of prostate cancer, confirmed by a tissue or cell test.
  • Be fully active or able to do light work, even if hard physical activity is limited (ECOG score of 0 or 1).
  • Have a PSA blood test level of at least 2 ng/mL at screening. PSA is a protein made by the prostate.
  • Have cancer that got worse after treatment to lower male hormones and at least one additional hormone treatment approved for prostate cancer that resists hormone-lowering treatment.

Who can't join

  • Have ever had cancer that spread to the brain.
  • Have a heart that does not work well or serious heart disease.
  • Have a major health problem, such as an active or uncontrolled infection, mental illness, or abnormal lab results, that the study doctor thinks makes joining unsafe or prevents participation.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. * Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening * Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Exclusion Criteria: * Participant must not have history of brain metastases. * Participant must not have impaired cardiac function or clinically significant cardiac disease. * Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment. Other protocol-defined inclusion/exclusion criteria apply

Study sites (8)

CA

FL

MA

NC

NY

TX

WA